Q-symbio:

Spectacular treatment of heart disease with Myoqinon

A 43% lower rate of heart-related mortality was the main outcome of the large international Q-Symbio study that is published in the esteemed Journal of the American College of Cardiology (JAAC). The study also provides strong evidence that daily intake of coenzyme Q10 nearly halves the risk of major adverse cardiac events (MACE). These results were achieved using the well-documented Pharma Nord preparation, Myoqinon Q10, which contains ubiquinone (the oxidized form of Q10) in a lipid solution. It does NOT contain the reduced form of Q10 (ubiquinol), also known as QH.

Now, try to compare such a result with the results of all other therapies for heart disease and you will understand why this specific study has attracted so much attention worldwide.

This web site expands on the results of the Q-Symbio study and the use of Myoqinon and provides answers to questions relating to Q10 and its many applications.

Myoqinon is a registered medical drug for adjuvant treatment of chronic heart failure (cardiomyopathy). Each capsule contains 100 mg of coenzyme Q10. Pharma Nord manufactures 100 mg coenzyme Q10 both in the form of a medical drug and as a nutritional supplement. The supplement version is called Bio-Quinone Q10 and is sold in over 45 countries across the globe.